Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Interest & Investment Income (2023 - 2026)

MBX Biosciences has reported Interest & Investment Income over the past 4 years, most recently at $3.7 million for Q1 2026.

  • Quarterly results put Interest & Investment Income at $3.7 million for Q1 2026, up 41.49% from a year ago — trailing twelve months through Mar 2026 was $12.2 million (up 53.36% YoY), and the annual figure for FY2025 was $11.1 million, up 76.72%.
  • Interest & Investment Income reached $3.7 million in Q1 2026 per MBX's latest filing, roughly flat from $3.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $3.7 million in Q1 2026 and bottomed at $783000.0 in Q3 2023.
  • Median Interest & Investment Income over the past 4 years was $2.3 million (2025), compared with a mean of $2.1 million.
  • Peak annual rise in Interest & Investment Income hit 198.88% in 2025, while the deepest fall reached 23.45% in 2025.
  • Over 4 years, Interest & Investment Income stood at $1.1 million in 2023, then soared by 163.41% to $3.0 million in 2024, then increased by 23.45% to $3.7 million in 2025, then grew by 0.4% to $3.7 million in 2026.
  • Business Quant data shows Interest & Investment Income for MBX at $3.7 million in Q1 2026, $3.7 million in Q4 2025, and $2.3 million in Q3 2025.